Next-generation Antibody Technologies Take Center Stage

Celltrion and Celltrion Pharmaceuticals are set to unveil their latest advancements in cancer treatment at the prestigious American Association for Cancer Research (AACR) Annual Meeting 2025, held in Chicago from April 25th to 30th. The presentations will highlight the companies’ progress in next-generation antibody technologies, including multi-antagonist antibodies and dual-payload Antibody-Drug Conjugates (adcs), sparking considerable interest from industry experts and investors alike.

Celltrion’s Multi-Antagonist Antibody: A Novel Approach to cancer Cell Elimination

Celltrion will present preclinical data on CT-P72, a multi-antagonist antibody targeting HER2-positive cancers, on April 27th. Developed in collaboration with ABPRO, CT-P72 is designed to induce cancer cell death by together binding to HER2-positive cancer cells and activating T-cells. This innovative approach, known as T-cell engaging (TCE) therapy, distinguishes CT-P72 from Celltrion’s existing ADC pipeline, promising a novel mechanism for targeted cancer treatment.

“CT-P72 represents a significant step forward in our efforts to develop more effective and targeted cancer therapies,”

HER2-positive breast cancer, such as, accounts for approximately 20-25% of all breast cancers. Targeted therapies like CT-P72 offer the potential to improve outcomes for patients with this aggressive form of the disease.

Celltrion Pharmaceuticals’ Dual-Payload ADC Platform: Enhancing Treatment Efficacy

Celltrion Pharmaceuticals will present a poster on April 30th detailing CTPH-02, a dual-payload ADC platform technology. This platform combines two distinct cytotoxic anticancer agents (payloads), aiming to deliver a more potent and precise therapeutic effect when conjugated with specific antibodies. The dual-payload approach is designed to overcome drug resistance and enhance the overall efficacy of ADC therapies.

Antibody-drug conjugates (ADCs) represent a rapidly growing area in cancer therapy.According to a recent report by Future Market Insights, the global ADC market is projected to reach US$ 43.7 Billion by 2033, growing at a CAGR of 14.8% from 2023 to 2033.

Synergistic R&D Efforts Drive Future Innovation

The parallel advancements in new drug pipeline development by Celltrion and platform technology innovation by Celltrion Pharmaceuticals are expected to create significant synergies in future research and development efforts. This collaborative approach positions the companies to accelerate the development of novel cancer therapies and solidify their presence in the pharmaceutical landscape.

Aspiring Pipeline Expansion: Targeting 13 Clinical Trial Submissions by 2028

Celltrion has set an ambitious goal to submit Investigational New Drug (IND) applications for 13 candidate materials by 2028, including nine ADCs and four multi-antagonist antibodies. Building on its success in developing the world’s first antibody biosimilars,the company aims to rapidly expand its new drug portfolio and establish itself as a key player in the innovative drug sector.

Recent Progress: CT-P70 Enters Phase 1 Clinical Trials

Celltrion recently received IND approval from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials for CT-P70, an ADC targeting CMET, a protein that promotes tumor growth in various cancers. The company also plans to submit IND applications for additional ADC candidates,such as CT-P71 and CT-P73,as well as the multi-antagonist drug CT-P72,later this year.